



# Episode Notes

The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of hospital corporations and are not intended to be personal medical advice.

# Episode 1 - ASCO GU 2024 Commentary: Prostate Cancer

1:29 – BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

9:50 - CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

19:03 - Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.

19:12 - Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical prostatectomy (RP).

28:12 – Treatment Intensification: What To Do for Patients With Early Castration-Resistant Prostate Cancer Who Have Received Doublet or Triplet Therapy. \*

\* This resource may be gated.

# Episode 2 - ASCO GU 2024 Commentary: Bladder Cancer

1:05 - Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.

1:15 - LBA6 - EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). <sup>††</sup>

5:50 - Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab).

·11:50 - AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.

15:23 - (CheckMate 274) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma <sup>††</sup>

20:19 - Keynote - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials <sup>\*</sup>

<sup>††</sup> These resources are not from the ASCO conference but were discussed on the podcast for context.

<sup>\*</sup> This resource may be gated.

# Episode 3 - ASCO GU 2024 Commentary: Kidney Cancer

1:31 - Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.

2:44 - Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial (Part A) <sup>††</sup>

6:56 - Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

16:00 – Subgroup analyses of efficacy outcomes by baseline tumor size in the phase 3, open-label CLEAR trial.

16:10 - Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.

17:12 - Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.

20:15 – Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

23:08 - Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.

<sup>††</sup> These resources are not from the ASCO conference but were discussed on the podcast for context.

\* This resource may be gated.

# Episode 4 - Putting Into Practice: GU24 Highlights

1:54 - BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).

6:26 - CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

10:02 - Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

16:58 - AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.

17:00 - (CheckMate 274) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma<sup>††</sup>

19:34 - Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.

<sup>††</sup> These resources are not from the ASCO conference but were discussed on the podcast for context.

# Episode 5 - Biochemical Recurrence in Prostate Cancer

8:00 - [PSMA-PET Registry for Recurrent Prostate Cancer \(PREP\)](#)

10:24 - [\(EMBARC\) Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer \\*](#)

17:10 - [\(PR7\) Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy](#)

20:49 - [PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer \(AFT-19\)\\*](#)

22:59 - [LBA02-11 UPDATED PROGRESSION-FREE SURVIVAL FROM PRESTO: A PHASE 3 RANDOMIZED STUDY OF ANDROGEN ANNIHILATION FOR HIGH-RISK BIOCHEMICALLY RELAPSED PROSTATE CANCER \(AFT-19\) #](#)

22:13 - [Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial \(NCT00268476\)](#)

25:08 - [\(STOMP\) Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial](#)

\* This resource may be gated.

# Dr. Wallis references hazard ratios of 0.53 (for ADT+APA+AAP vs ADT) and 0.59 (for APA+ADT vs ADT) from the AUA 2023 report. Please note a more recent update from the PRESTO study, published in JCO 2024 (discussed at 20:49 of the podcast) reports hazard ratios of 0.48 (for ADT+APA+AAP vs ADT) and 0.52 (for APA+ADT vs ADT).

# Episode 6 - See you at the next meeting? The intersection of medicine and politics

3:08 - Taking a Stand: No Conferences in Anti-abortion States\*

7:27 - Attitudes Among Society of Women in Urology Members Toward Dobbs v. Jackson Women's Health Organization \*

9:44 - Economic Significance of Meetings to the US Economy

19:56 - Abortion restrictions and medical residency applications \*

20:02 - Trends in Obstetrics and Gynecology Residency Applications in the Year After Abortion Access Changes

20:11 - Practice Location Preferences in Response to State Abortion Restrictions Among Physicians and Trainees on Social Media

\* This resource may be gated.

## Episode 7 - Does physician gender matter? Impact on surgical outcomes, patient care and more

1:03 - 13th Annual Juravinski Cancer Centre (JCC) and Walker Cancer Centre Uro-oncology Forum 2024

2:48 - Comparison of postoperative outcomes among patients treated by male and female surgeons: a population based matched cohort study

6:18 - Comparison of Hospital Mortality and Readmission Rates for Medicare Patients Treated by Male vs Female Physicians

6:55 - Association Between Anesthesiologist Sex and Patients' Postoperative Outcomes: A Population-based Cohort Study  
\*

7:26 - Patient-physician gender concordance and increased mortality among female heart attack patients

\* This resource may be gated.



# Episode 8 - Oncology trial design and statistics with Dr. Pavlos Msaouel

2:38 - [Decoding Randomized Controlled Trials: An Information Science Perspective](#)

7:23 - [Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy](#)

11:05 - [Interpreting Randomized Controlled Trials \(see section 10, "Comparative and Group-Specific Inferences"\)](#)

20:41 - [Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive](#)

22:14 - [\(COSMIC-313\) Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma](#)

24:38 - [Nivolumab plus ipilimumab \(NIVO+IPI\) vs sunitinib \(SUN\) for first-line treatment of advanced renal cell carcinoma \(aRCC\): Long-term follow-up data from the phase 3 CheckMate 214 trial.](#)

31:26 - [Causal Inference About the Effects of Interventions From Observational Studies in Medical Journals](#)

\* This resource may be gated.

# Episode 9 - ASCO Annual Meeting 2024 Commentary: Kidney Cancer

2:00 - Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).

3:44 - Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.

10:24 - Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

10:36 - Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).

13:30 - Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.

16:22 - Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).

20:23 - Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

21:52 - A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

# Episode 10 - ASCO Annual Meeting 2024 Commentary: Bladder Cancer

00:56 - Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node-only metastatic urothelial carcinoma from the CheckMate 901 trial.

8:30 - Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).

8:39 - Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.

14:04 – Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.

21:09 - Gilead Provides Update on Phase 3 TROPiCS-04 Study

# Episode 11 - ASCO Annual Meeting 2024 Commentary: Prostate Cancer

1:00 - A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.

9:23 - Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).

14:39 - Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore).

23:20 - Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.

25:28 - EMBARC post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).

26:41 - Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).

# Episode 12 - Radiation for Prostate Cancer with Dr. Andrew Loblaw (Part 1)

3:18 - Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

3:59 - 5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer \*

4:28 - Once-weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): A phase 2 randomized trial \*

6:20 - Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

7:19 - Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update

8:36 - Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer (PR19).

\* This resource may be gated.

# Episode 12 - Radiation for Prostate Cancer with Dr. Andrew Loblaw (Part 1) Cont'd

9:06 - Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer

9:59 - Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (ASCENDE-SBRT or PR24)

12:13 - Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial

14:00 - An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

14:02 - Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

15:55 - Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis\*

16:13 - Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy (STAMPEDE)

\* This resource may be gated.

# Episode 13 - Radiation for Prostate Cancer with Dr. Andrew Loblaw (Part 2)

1:57 - Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial

5:32 – Tendulkar nomogram

5:57 - Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

7:02 - Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial \*

12:46 - Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

13:25 - Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer The EXTEND Phase 2 Randomized Clinical Trial

\* This resource may be gated.